Literature DB >> 6414699

Therapeutic effects of single-push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna.

H O Klein, P D Wickramanayake, E Christian, C Coerper, L Graf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6414699     DOI： 10.1016/s0305-7372(83)80012-7

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

1.  Basic principles in preclinical cancer chemotherapy.

Authors:  N Brock; J Pohl; B Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.

Authors:  J C Cervellino; C E Araujo; C Pirisi; O Sanchez; M Brosto; R Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.

Authors:  D M Nanus; D P Kelsen; R Lipperman; M Eisenberger
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

4.  Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).

Authors:  H O Klein; P D Wickramanayake; E Christian; C Coerper
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  Toxicity of high-dose ifosfamide in children.

Authors:  S M Davies; A D Pearson; A W Craft
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.

Authors:  H Jürgens; U Exner; J Kühl; J Ritter; J Treuner; P Weinel; K Winkler; U Göbel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.